L3VLUP
ProSign in

GSK in the 13F filings

GSK PLC · CUSIP 37733W204

Sector · Pharmaceuticals and biotechnologyTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Pharmaceutical preparations
Quarter
Q3 2026 · early filersQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023
Quarter end
30 Jun 2024
the date the book describes
Filed
5 Nov 2026
latest of these filings; the earliest 6 Aug 2024
Managers listing it
10
at least, of 95 tracked, among listed positions
Comparable managers
94
filed both Q1 2024 and Q2 2024; 9 listed it in both
Shares listed
119,986,003
combined, among listed positions
Reported value
$4.6bn
combined, at the quarter end

Among the 94 comparable managers: 6 buyers (opened or added shares) and 4 sellers (trimmed or exited), at least, among listed positions. Their net change in shares is not known from listed positions, because at least one of them lists it in only one of the two quarters.

Managers listing GSK in Q2 2024

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2024, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

10 of 10 holders

ActionFiling
Dodge & Cox68,337,138$2.6bn1.58%Trimmed-525,17013 Aug 2024 (the filing on sec.gov)
Fidelity (FMR LLC)26,784,583$1.0bn0.07%Added+2,203,3615 Nov 2026 (the filing on sec.gov)
T. Rowe Price Associates Inc10,232,276$394munder 0.1%Trimmed-1,233,13714 Aug 2024 (the filing on sec.gov)
Holocene Advisors LP5,689,695$219m0.91%Trimmed-3,029,94914 Aug 2024 (the filing on sec.gov)
Arrowstreet Capital LP2,578,747$99m0.09%Added+472,47514 Aug 2024 (the filing on sec.gov)
Renaissance Technologies LLC2,347,993$90m0.15%Added+554,6009 Aug 2024 (the filing on sec.gov)
Capital Research Global Investors1,754,493$68munder 0.1%Added+1,45813 Aug 2024 (the filing on sec.gov)
Acadian Asset Management LLC1,710,252$66m0.20%Trimmed-509,5466 Aug 2024 (the filing on sec.gov)
Bridgewater Associates LP465,826$18m0.09%Added+330,53214 Aug 2024 (the filing on sec.gov)
Hudson Bay Capital Management LP85,000$3.3munder 0.1%Newnew14 Aug 2024 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2024 to Q2 2024, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
10 in Q3 2024 to 11 in Q2 2026

Tracked managers listing it, at least.

051015202023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
GSK by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20221$19mn.a.n.a.
Q3 202218$3.9bnn.a.n.a.
Q4 202218$4.9bnn.a.n.a.
Q1 202313$4.4bnn.a.n.a.
Q2 202313$4.3bnn.a.n.a.
Q3 202316$4.5bnn.a.n.a.
Q4 202313$4.5bn67
Q1 202413$5.3bn57
Q2 202410$4.6bn64
Q3 202410$4.9bn63
Q4 202413$4.9bn112
Q1 202511$6.3bn76
Q2 202510$6.2bn83
Q3 202511$7.5bn65
Q4 202511$8.8bn1513
Q1 20269$9.1bn919
Q2 202611$7.5bn1512

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

GSK and LLY →GSK and JNJ →GSK and VRTX →Choose a stock to compare with GSK →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own GSK, latest filings →Back to the 13F Explorer →